LIFESAVING After being on the Be the Match registry for eight months, Lacey Jones donated stem cells to a 75-year-old woman battling myeloid leukemia.
A Kokomo teacher has spent part of her summer possibly saving the life of a 75-year-old woman.
Late last month, Lacey Jones, a veterinary careers instructor at the Kokomo Area Career Center, traveled to the Hoxworth Blood Center at the University of Cincinnati to donate stem cells to a woman she was genetically matched with who was battling myeloid leukemia. Now, all Jones hopes is that her stem cells were enough.
I really want nothing more than to hear that she is in remission. That was the emotional part of the process. Once it was all over, I just went to my hotel room, and I could not help but to just kind of cry and cry and cry and pray and hope because you want nothing more than for your cells to work for the patient, Jones said.
But the opportunity to help someone was a chance that some dont ever get. Jones registered as a donor through Be the Match, which operates the national bone marrow registry, late last year after the story of her friends daughter, who was diagnosed with infant leukemia, inspired her to want to help someone.
According to Be the Match, only one of 430 people who register as a donor is selected as a match, and some of those who are selected wait years before theyre matched. For Jones, she became a genetic match for someone in just eight months.
At the end of May, she received a call from Be the Match, letting her know that there was a woman who had been diagnosed with myeloid leukemia, and Jones was a secondary match for her. Jones was told that there was someone who was the primary match who matched just a little better, but in the chance that that donor fell through, Jones would be at the plate.
I just kind of waited around, didnt really think anything of it, and then they called me at the beginning of June. She explained that the original person who matched ended up not being who they really needed, and of course with HIPPA and all that they cant really tell you any of that information as to why, Jones said.
As far as the patient, all Jones was told was that it was a 75-year-old woman who was battling myeloid leukemia somewhere in the world. Jones was asked if shed be available to donate during certain dates, but at that point, there were no details as to where she would be donating or exactly when. What Jones did know, though, was that she would do it.
The process then became a whirlwind of scheduling, logistics, and injections. She went to Indianapolis for lab work to ensure she was healthy enough to donate. Then, for a week leading up to her donation, she was required to take injections of a drug called filgrastim to increase the number of white blood cells in her bloodstream so they could be collected more easily.
Theyre actual injections that are given to people who have cancer to increase the white blood cell count, but theyre given to donors because it increases your bone marrow production. Then what happens is your body naturally expels the extra bone marrow into the bloodstream, she said.
Jones was a bit hesitant because shed never given herself injections before, and she was warned of the side effects that could occur. The most common side effect of filgrastim, she said, was soreness due to the overproduction of bone marrow.
They explained some of the side effects of the filgrastim, and that makes you feel a little intimidated. But because of my passion and my empathy for the patient and hearing about there not being donors and just knowing that I could potentially help save her life, it overruled any type of fear I had, she said.
At the end of June, Jones traveled to Hoxworth Blood Center at the University of Cincinnati to begin the donation.
Now, more than ever, the world needs trustworthy reportingbut good journalism isnt free.Please support us by making a contribution.
There are two donation methods, either marrow or peripheral blood stem cells. The marrow donation is a surgical procedure done under anesthesia. Doctors use needles to retrieve liquid marrow from both sides of the back of a patients pelvic bone. The hospital stay is usually from early morning to late afternoon, according to Be the Match, while some donors are kept overnight for observation.
The peripheral stem cell donation, on the other hand, is a non-surgical procedure that takes place at a blood center or outpatient hospital. Blood is removed through a needle in one arm and passed through a machine that collects only the blood-forming cells and returns the blood through a needle in the donors other arm.
As soon as Jones got to the blood center, nurses took a blood sample to see where her white blood cell count was. A normal count, she said, was between four and 10. Hers was at 42. Because the filgrastim injections were so effective for Jones, she was able to do the peripheral stem cell method.
So began a five-hour process of Jones sitting very still while a machine filtered out blood-forming cells from her left arm and put the blood back in her right arm. The nurses took her blood pressure every 15 minutes to ensure she wasnt having any kind of reaction, and the staff knew down to the minute when her donation would be complete, she said, and had the transfer staff ready.
At the end of the donation, Jones said it was like a movie when the person came in to take her stem cells that would be delivered to the patient.
They actually had somebody come up with the cooler because they flew my sample to the patient. Its almost like a movie. You watch someone come through the big steel door with the cooler and watch them package your sample, she said.
And while she didnt know where the sample was going, she was told the recipient was nowhere close to where they were.
When the process was over, Jones was thankful. She said the nurses told her it was a textbook donation, and the only side effect Jones experienced from the injections was mild soreness.
Three months after the donation, the recipient will have the option to find out who her donor was and to contact Jones if she chooses.
Jones said shed love to one day hear from the recipient.
I want nothing more than to one day get that phone call that says, OK, the person you donated to wants to get in contact with you. I dont know what Ill do. Ill probably cry again, she said.
Jones will remain on the Be the Match registry, and in the event she ever receives a call that shes a match again, she will be ready to go, she said.
To join the bone marrow donor registry, visit join.bethematch.org. The process requires a cheek swab, which can be done with a kit thats mailed to potential donors. Afterward, the person will be added to the registry and have the chance to get matched.
Be the Match encourages those who are contacted to donate to go forward with the donation as theyre the patients best genetic match from the entire registry.
- Issue: Cell Stem Cell - August 2nd, 2021
- Stem Cell Therapy & Alternative Medicine in Mexico ... - August 2nd, 2021
- Fetal Stem Cell - an overview | ScienceDirect Topics - August 2nd, 2021
- Stem cell therapy - SlideShare - August 2nd, 2021
- Essent Biologics Launches Human Mesenchymal Stem Cells For ... - August 2nd, 2021
- From Cells to Organs: The Present and Future of Regenerative Medicine - DocWire News - August 2nd, 2021
- USC Stem Cell scientists explore the latent regenerative potential of the inner ear - USC News - August 2nd, 2021
- Refining epilepsy treatment with brain organoids and AI - Monash University - August 2nd, 2021
- Astellas and Minovia link up on mitochondrial cell therapy programs - The Pharma Letter - August 2nd, 2021
- Stem Cell Scientists Explore the Latent Regenerative Potential of the Inner Ear - SciTechDaily - July 31st, 2021
- Colin Jackson health: Im in constant pain Athlete to undergo stem cell therapy to help - Express - July 31st, 2021
- The Talking Man: New Advances In Regenerative Medicine - Forbes - July 31st, 2021
- Medipost's clinical trial approved to evaluate efficacy of knee osteoarthritis treatment - Aju Business Daily - July 31st, 2021
- A Phase II Study of Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide Before Stem Cell Transplantation in People with... - July 31st, 2021
- Background should not be a barrier to access stem cell transplant treatment and care - PoliticsHome - July 31st, 2021
- Treatment Approaches for Patients With R/R DLBCL - Targeted Oncology - July 31st, 2021
- Global $57.4 Billion Cell And Gene Therapy Manufacturing Market to 2028 - Rising Pressure on Drug Developers/Manufacturers to Meet the Growing Market... - July 31st, 2021
- Acute Myeloid Leukemia Fungal Infections: Types and Treatment - Healthline - July 31st, 2021
- Overview of DLBCL - Targeted Oncology - July 31st, 2021
- Roundtable Discussion: Participants Evaluate the Use of Transplant and MRD in Newly Diagnosed Multiple Myeloma - Targeted Oncology - July 31st, 2021
- Hematopoietic Stem Cell Transplantation (HSCT) Market: Allogeneic transplant is projected to continue to hold a dominant market share - BioSpace - July 27th, 2021
- Researchers develop a cell culture test to detect substances that harm the placenta and embryo - News-Medical.net - July 27th, 2021
- FDA Approves KEYTRUDA (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With... - July 27th, 2021
- Cryopreservation of Unrelated Donor SCTs Safe, Effective in Patients Who Underwent HSCT - Hematology Advisor - July 27th, 2021
- Combination drug therapy can significantly benefit patients with newly diagnosed blood cancer - The Institute of Cancer Research, London - The... - July 25th, 2021
- Study proposes repurposed drug to treat COVID-19 - The Hindu - July 25th, 2021
- Injecting mice with pulmonary endothelial cells can reverse symptoms of emphysema - News-Medical.Net - July 25th, 2021
- FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum - July 23rd, 2021
- Stemming the tide of stem-cell treatment scams - Houston Chronicle - July 23rd, 2021
- Regenerative Medicine provides new hope and healing - Summit Daily News - July 23rd, 2021
- Emphysema Reversed in Mice Given Injection of Healthy Pulmonary Endothelial Cells - Genetic Engineering & Biotechnology News - July 23rd, 2021
- Nelson: Gimpy girls have different means of recovery - Watertown Public Opinion - July 23rd, 2021
- Gene Therapy Protects Optic Nerve Cells and Vision in Mice with Retinal Injury and Glaucoma - Genetic Engineering & Biotechnology News - July 23rd, 2021
- Has COVID-19 Opened up the Route to Market for Cell and Gene Therapy? - Pharmaceutical Executive - July 23rd, 2021
- Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments - OncLive - July 23rd, 2021
- Bluebird, with little fanfare, is first to bring a second gene therapy to market - BioPharma Dive - July 23rd, 2021
- Belumosudil Granted Full Approval for Treatment of Chronic GVHD by FDA - Cancer Network - July 21st, 2021
- Creative Medical Technology Holdings Announces MyeloCelz The Company's Second Regenerative Immunotherapy Product - PRNewswire - July 21st, 2021
- Stem Cell Therapy Gets Fast Track Status for Parkinson Disease - Monthly Prescribing Reference - July 21st, 2021
- Stem cell model reveals how COVID-19 can infect the brain - Study Finds - July 21st, 2021
- Young Patients With Multiple Myeloma May Benefit From Tandem Autologous Hematopoietic Stem Cell Transplantation - Hematology Advisor - July 21st, 2021
- Emerging Quadruplets, Novel Targets, and Immunotherapy Advances Personalized Medicine in Multiple Myeloma - OncLive - July 21st, 2021
- BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease - Yahoo Finance - July 21st, 2021
- YOUR HEALTH: Finding cures by tracking cells - WQAD.com - July 21st, 2021
- Study shows promise of combining radiation therapy with dendritic-cell vaccines for breast cancer - News-Medical.Net - July 21st, 2021
- Profilin 1 Protein and Its Implications for Cancers - Cancer Network - July 17th, 2021
- Developmental Interest in Allogeneic PlacentaDerived Cell Therapies Expands - OncLive - July 17th, 2021
- For Patients with HIV and Cancer, a Multidisciplinary Treatment Approach is Critical - Targeted Oncology - July 17th, 2021
- Times really up! FDA authority to crack down on regenerative medicines upheld as grace period ends - JD Supra - July 15th, 2021
- The Memphis Institute of Regenerative Medicine Rebrands To Reflect Statewide Reach - UTHSC News - July 15th, 2021
- Dr. Sperling on Future Research With CAR T-Cell Therapy in Multiple Myeloma - OncLive - July 15th, 2021
- TiTAN-1 Trial of GEN-011 Initiates Treatment in Patients With Solid Tumors - Targeted Oncology - July 15th, 2021
- Saving a life, fixing the world - The Jewish Standard - July 15th, 2021
- Exosome spray may be better able to heal damaged hearts - New Atlas - July 15th, 2021
- Prime Medicine uncloaks with $315M to push 'search and replace' gene editing treatments - FierceBiotech - July 13th, 2021
- Dr. Sallman on Unmet Treatment Needs in Higher-Risk MDS - OncLive - July 13th, 2021
- U.S. Stem Cell, Inc The New Generation Company In The ... - July 11th, 2021
- Stem Cell Therapy - Stemedix | Regenerative Medicine Also ... - July 11th, 2021
- FIRM, CAS further cooperate to advance reproductive medicine research_china.org.cn - China.org.cn - July 11th, 2021
- England's drug price watchdog rejects Orchard's groundbreaking gene therapy after first round of talks - FiercePharma - July 11th, 2021
- ARO-HIF2 Shows Signals of Activity, Safety in Clear Cell Renal Cell Carcinoma - Targeted Oncology - July 9th, 2021
- Gene therapy for sickle cell disease: progress and competition - BioPharma Dive - July 9th, 2021
- Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere... - July 9th, 2021
- Dr. Sperling on Future Research Directions With Ide-Cel in Multiple Myeloma - OncLive - July 9th, 2021
- More than $25m awarded to Monash researchers for vital medical research - Monash University - July 9th, 2021
- Magnetically-guided delivery of therapeutic stem cells into the brain - Advanced Science News - July 7th, 2021
- Beyond CAR-T: New Frontiers in Living Cell Therapies - UCSF News Services - July 7th, 2021
- Stem cell therapy could make significant impact as opioid alternative - The Pharma Letter - July 7th, 2021
- Institute for Stem Cell Biology and Regenerative Medicine ... - July 5th, 2021
- Home - World Stem Cell Summit - July 5th, 2021
- Stem Cell Therapy & Regenerative Medicine Clearwater, FL ... - July 5th, 2021
- Ethical Issues in Stem Cell Research - July 5th, 2021
- Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com - Business Wire - July 3rd, 2021
- Regenerative Therapy Makes Headway in HF ... in the Right Patients - MedPage Today - July 3rd, 2021
- A New Era For FDA Regulation Of Cell And Tissue Products - Law360 - July 3rd, 2021
- Multiple myeloma treatment: Newest options, drugs, and more - Medical News Today - July 3rd, 2021
- Anti-CD22 CAR-T cell therapy as a salvage treatment - OTT | OTT - Dove Medical Press - July 3rd, 2021
- Studies Offer Promising Data on CAR T-cell Therapy in B-ALL, Multiple Myeloma - AJMC.com Managed Markets Network - July 3rd, 2021
- The cell therapy manufacturing market is projected to reach USD 14.5 billion by 2030, growing at - GlobeNewswire - July 3rd, 2021
- Cellular Model of a Developing Mouse Is Built With Spatial Resolution - Technology Networks - July 3rd, 2021